Opdivo (nivolumab)

pCPA File Number: 22041

Negotiation Status:

Concluded with an LOI

Indication(s):

Indicated as monotherapy for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC

Sponsor/Manufacturer:

Bristol Myers Squibb Canada Inc.

CADTH Project Number:

PC0272

pCPA Engagement Letter Issued:

2022-12-09

Negotiation Process Concluded:

2022-12-23